SERVICES

Trial Design, Submission & Approvals

Design smarter studies, de-risk regulatory pathways, and get to approval faster with integrated scientific, regulatory, and feasibility expertise.

Proven Clinical Excellence

Our streamlined processes and regulatory expertise deliver rapid approvals and significant cost efficiencies for our partners.

REGULATORY SUCCESS

0%

0%

of Clinical Trial Applications approved by regulators (MHRA, FDA), ensuring a seamless path to study start.

COST EFFICIENCY

0%

0%

Cost savings generated for multiple clients through innovative trial design.

THERAPEUTIC EXPERTISE

0

0

CNS indications we’ve worked with, providing deep specialized knowledge.

SPEED TO SUBMISSION

0 months

0 months

Average time from trial concept to Clinical Trial Application submission.

RAPID START-UP

0 weeks

0 weeks

As little as 3 weeks between contracting and submission for expedited timelines.

Why sponsors work with us

Why sponsors work with us

Agile, responsive delivery

A small, highly specialised team means faster decisions, flexible resourcing and direct access to senior experts throughout your study.

Deep operational expertise in CNS and controlled substances

Our team brings hands-on experience managing Schedule 1–4 compounds and complex psychiatric protocols across diverse trial settings.

Integrated with a high-performing site network

Close coordination with our London and NHS-embedded sites allows smoother start-up, quicker issue resolution and stronger alignment between project teams and delivery teams.

Global experience, local execution

Our project leaders and monitors have overseen studies across the UK, EU and US, bringing global standards to a focused UK delivery model.

Aligned time zones for US and EU sponsors

UK hours offer optimal overlap with both US East Coast and Europe, enabling real-time communication and rapid turnaround.

CHIEF SCIENTIFIC OFFICER

Henry Fisher

Oxford PhD in CNS drug delivery. Started his career at the Beckley Foundation in 2015. Since then Henry has founded three companies in the psychedelics and cannabis sectors and advised clients on R&D strategies, IP generation and research operations. ​